Alto Neuroscience, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2830 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer - Aug 27th, 2026 2:05 pm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Aug 16th, 2026 2:07 pm
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Aug 16th, 2026 2:08 am
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Aug 15th, 2026 9:16 pm
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 12th, 2026 2:03 pm
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock - Jul 13th, 2026 5:47 am
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Jul 2nd, 2026 1:58 pm
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia - Jun 15th, 2026 6:03 am
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing - May 26th, 2026 11:19 pm
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss - Apr 2nd, 2026 2:10 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Apr 2nd, 2026 1:57 pm
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - Apr 2nd, 2026 12:36 pm
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - Apr 2nd, 2026 6:20 am